These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
118 related articles for article (PubMed ID: 9179944)
1. Effectiveness of nilvadipine in two cases of chronic schizophrenia. Yamada K; Ashikari I; Onishi K; Kanba S; Yagi G; Asai M Psychiatry Clin Neurosci; 1995 Aug; 49(4):237-8. PubMed ID: 9179944 [TBL] [Abstract][Full Text] [Related]
2. Nilvadipine is effective for chronic schizophrenia in a double-blind placebo-controlled study. off. Yamada K; Kanba S; Ashikari I; Ohnishi K; Yagi G; Asai M J Clin Psychopharmacol; 1996 Dec; 16(6):437-9. PubMed ID: 8959468 [TBL] [Abstract][Full Text] [Related]
3. A clinical trial of nifedipine in schizophrenia and tardive dyskinesia. Suddath RL; Straw GM; Freed WJ; Bigelow LB; Kirch DG; Wyatt RJ Pharmacol Biochem Behav; 1991 Jul; 39(3):743-5. PubMed ID: 1686106 [TBL] [Abstract][Full Text] [Related]
4. Effects of nifedipine, a calcium channel antagonist, on cognitive function in schizophrenic patients with tardive dyskinesia. Schwartz BL; Fay-McCarthy M; Kendrick K; Rosse RB; Deutsch SI Clin Neuropharmacol; 1997 Aug; 20(4):364-70. PubMed ID: 9260735 [TBL] [Abstract][Full Text] [Related]
5. Effects of nifedipine on psychosis and tardive dyskinesia in schizophrenic patients. Stedman TJ; Whiteford HA; Eyles D; Welham JL; Pond SM J Clin Psychopharmacol; 1991 Feb; 11(1):43-7. PubMed ID: 1674950 [TBL] [Abstract][Full Text] [Related]
6. Clozapine treatment for neuroleptic-induced tardive dyskinesia, parkinsonism, and chronic akathisia in schizophrenic patients. Spivak B; Mester R; Abesgaus J; Wittenberg N; Adlersberg S; Gonen N; Weizman A J Clin Psychiatry; 1997 Jul; 58(7):318-22. PubMed ID: 9269253 [TBL] [Abstract][Full Text] [Related]
7. Nifedipine in the treatment of tardive dyskinesia. Duncan E; Adler L; Angrist B; Rotrosen J J Clin Psychopharmacol; 1990 Dec; 10(6):414-6. PubMed ID: 1981070 [TBL] [Abstract][Full Text] [Related]
14. ICI 204,636, a novel, atypical antipsychotic: early indication of safety and efficacy in patients with chronic and subchronic schizophrenia. Fabre LF; Arvanitis L; Pultz J; Jones VM; Malick JB; Slotnick VB Clin Ther; 1995; 17(3):366-78. PubMed ID: 7585841 [TBL] [Abstract][Full Text] [Related]
15. Chronic hemorheological effects of the calcium antagonist nilvadipine in essential hypertension. Tsuda Y; Satoh K; Kitadai M; Izumi Y; Takahashi T Arzneimittelforschung; 1997 Aug; 47(8):900-4. PubMed ID: 9296274 [TBL] [Abstract][Full Text] [Related]
16. A randomized controlled trial of risperidone and olanzapine for schizophrenic patients with neuroleptic-induced tardive dyskinesia. Chan HY; Chiang SC; Chang CJ; Gau SS; Chen JJ; Chen CH; Hwu HG; Lai MS J Clin Psychiatry; 2010 Sep; 71(9):1226-33. PubMed ID: 20441726 [TBL] [Abstract][Full Text] [Related]
17. The prevalence of tardive dyskinesia after a nine month naturalistic randomized trial comparing olanzapine with conventional treatment for schizophrenia and related disorders. de Jesus Mari J; Lima MS; Costa AN; Alexandrino N; Rodrigues-Filho S; de Oliveira IR; Tollefson GD Eur Arch Psychiatry Clin Neurosci; 2004 Dec; 254(6):356-61. PubMed ID: 15538607 [TBL] [Abstract][Full Text] [Related]
18. Nilvadipine: profile of a new calcium antagonist. An overview. Rosenthal J J Cardiovasc Pharmacol; 1994; 24 Suppl 2():S92-107. PubMed ID: 7898101 [TBL] [Abstract][Full Text] [Related]
20. Long-term clinical effect of nilvadipine in patients with chronic heart failure: a double-blind placebo-controlled study. Hori M; Sato H; Karita M; Kodama K; Hoki N; Hayashi T; Naka M; Nanto S; Yamada Y; Kamada T Heart Vessels; 1994; 9(5):249-53. PubMed ID: 7814301 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]